Amolyt Pharma to Present Data on the Renal Effects of Eneboparatide, a PTHR1 Agonist in Phase 3 for the Treatment of Hypoparathyroidism, at the 39th Congress of the French Society of Endocrinology
LYON, France and CAMBRIDGE, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global company specialized in developing therapeutic...